Life Sciences Real Estate Development: Site Criteria, Lab Specs, and What AI Can Automate
What institutional developers need to know about lab and life sciences buildings before breaking ground.
Life sciences real estate has moved from niche to institutional. Alexandria Real Estate Equities, BioMed Realty, Tishman Speyer, and Blackstone have all scaled their life sciences development platforms over the past five years. The sector attracted significant new supply commitments between 2020 and 2024, with primary clusters in Boston/Cambridge, San Francisco Bay Area, and San Diego.
Supply discipline is now the real issue. Vacancy in Boston's Kendall Square submarket climbed above 20% in late 2024 as speculative lab space met a slower biotech funding environment, according to CBRE market data. That correction is filtering out opportunistic developers and raising the bar on technical knowledge.
For developers considering or actively building in life sciences, the requirements are significantly more demanding than standard office or industrial. Here is what those requirements look like, and where AI is starting to help.
What Makes a Good Life Sciences Site
Life sciences facilities are not office buildings with better plumbing. Site selection for lab and R&D space involves a different set of criteria.
Proximity to research anchors. The most durable life sciences clusters are anchored by research universities and teaching hospitals. MIT and Harvard anchor Cambridge. UCSF anchors Mission Bay. Johns Hopkins anchors Baltimore's emerging cluster. Tenant demand for proximity to talent and collaborative research is structurally embedded in the sector, not a preference -- it is a requirement for many biotech firms at the research stage.
Floor-to-floor heights. Standard office buildings have 9-10 foot floor-to-floor heights. Lab buildings typically require 14-16 feet minimum to accommodate mechanical systems, fume hoods, and process equipment. Adaptive reuse of older office stock often fails here. The structural cost to raise slabs is prohibitive in most cases.
Power density. Lab buildings run at 150-300 watts per square foot, compared to 5-15 watts for conventional office. Sites need proximity to high-capacity utility infrastructure, and building design must accommodate redundant power and cooling systems from day one.
Chemical storage and waste. Life sciences tenants work with hazardous materials. Sites must comply with fire code requirements for chemical storage, including segregation by compatibility class. Local permitting regimes vary significantly on how these uses are classified and what approvals are required.
Vibration isolation. Some research equipment, particularly electron microscopes and precision imaging systems, is sensitive to vibration. Sites near rail corridors or heavy truck routes may require expensive structural mitigation -- a cost that needs to be underwritten at the site selection stage, not discovered at design development.
Tenant Requirements: What Institutional Tenants Actually Need
The life sciences tenant spectrum runs from venture-backed biotech startups in flex lab space to large pharmaceutical companies requiring GMP (Good Manufacturing Practice) manufacturing suites.
For institutional developers, the relevant tenant tier is mid-stage biotech (Series B through IPO) and established pharma and medtech companies. Their requirements:
Wet lab infrastructure. Plumbing for deionized water, lab gas distribution (compressed air, nitrogen, vacuum), and floor drains rated for chemical disposal
HVAC precision. Lab areas require 6-12 air changes per hour with precise humidity and temperature control, compared to 4-6 for standard office
Emergency power. 100% backup generator coverage is increasingly standard for tenants running live experiments and cell culture programs
Flexibility. Tenant build-outs change frequently as research programs evolve. Structural grids that support flexible partition placement and modular utility distribution reduce re-leasing friction and improve asset durability
Where AI Is Adding Value
Life sciences development is technically complex and data-intensive. AI has genuine traction in several workflow areas.
Site screening. AI tools can layer proximity-to-anchor-institution scoring with utility availability, zoning compatibility, and floor plate constraints to shortlist candidate sites faster. What takes a development analyst a week can be reduced to a day, with a more consistent scoring methodology.
Regulatory database parsing. Lab buildings require navigating OSHA's laboratory safety standards (29 CFR 1910.1450), EPA waste regulations, and local fire codes. AI can parse these regulatory overlays and flag conflicts with proposed program before the design team engages, catching issues that otherwise surface at permit submission.
Lease abstraction. Life sciences leases are complex. Tenant improvement allowances are larger, fit-out standards are highly specific, and early termination provisions are more common due to funding volatility. AI document review tools can extract and summarize these provisions at scale across a portfolio.
Market demand analysis. Tracking biotech funding by geography and stage provides a leading indicator of lab demand. AI tools can monitor NIH grant allocations, FDA approvals, and Series B/C funding activity to project near-term absorption by cluster. This is more predictive than trailing vacancy data alone.
Where AI is limited. Life sciences development requires hands-on engagement with research institution procurement teams, local economic development agencies, and specialized MEP engineers. These relationships and technical negotiations remain human work. AI cannot assess whether a university research anchor will actually drive tenant demand to a specific submarket.
The Supply Correction and What It Means for New Development
The 2024-2025 supply correction in primary clusters is not uniform. Boston/Cambridge and the SF Bay Area are working through speculative overhang. San Diego remains tighter. Secondary markets including Raleigh-Durham, Houston, and Philadelphia are absorbing new supply more steadily, supported by academic medical center expansion and lower barriers to entry.
For new development underwriting, the relevant questions are:
Is the proposed program serving early-stage flex demand or established tenant build-to-suit?
Is there an anchor tenant or pre-leasing commitment?
How does the proposed floor plate flexibility compare to competitive alternatives in the submarket?
What is the realistic hold period given current absorption rates?
The developers who will perform through the correction are the ones with the deepest technical knowledge of tenant requirements and the most disciplined site selection criteria. AI accelerates the research that supports those decisions. The technical expertise has to be there first.